Solid state form of zavegepant hydrochloride and process for preparation thereof
Crystalline polymorphs of Zavegepant hydrochloride, particularly Form C6, address the need for improved processing and stability, enhancing pharmaceutical formulations for oral and intranasal administration, thus improving treatment efficacy for conditions like migraine and headaches.
Patent Information
- Application Number
- PCT/IB2026/054861
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-03-02
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
There is a need for additional salts and solid state forms of Zavegepant to improve processing properties, stability, and bioavailability, as existing forms may not adequately address these factors.
The development of crystalline polymorphs of Zavegepant hydrochloride, particularly the crystalline methyl ethyl ketone solvate (Form C6), which offers improved solubility, bulk properties, and stability, facilitating the preparation of pharmaceutical compositions for oral and intranasal administration.
The crystalline polymorphs enhance the processing and handling characteristics of Zavegepant hydrochloride, providing better stability, solubility, and suitability for pharmaceutical formulations, especially for intranasal administration, thereby improving treatment efficacy for conditions like migraine and headaches.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000011_0001_TABLE 
Figure IMGF000011_0002_TABLE
Abstract
Description
Attorney Docket: APHlO-WOOl (2222-224 PCT)SOLID STATE FORM OF ZAVEGEPANT HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of, and priority to, U.S. Provisional Patent Application Serial No. 63 / 807,023 filed on May 16, 2025, and U.S. Provisional Patent Application Serial No. 63 / 994,243 filed March 2, 2026. The entire contents of the foregoing applications are incorporated by reference herein.FIELD OF THE DISCLOSURE
[0002] The present disclosure encompasses solid state forms of Zavegepant hydrochloride, in embodiments crystalline polymorphs of Zavegepant hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof.BACKGROUND OF THE DISCLOSURE
[0003] Zavegepant, ( / ?)-V-(3-(7-methyl-l / 7-indazol-5-yl)-l-(4-(l-methylpiperidin-4-yl)piperazin- 1 -yl)- 1 -oxopropan-2-yl)-4-(2-oxo- 1 ,2-dihydroquinolin-3 -y l)piperidine- 1 -carboxamide, has the following chemical structure:
[0004] Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, and it is developed for acute treatment of migraine or headaches. It was also investigated for the treatment of COVID- 19 respiratory infection.
[0005] The compound is described in International Publication No. WO2011 / 123232 and in Org. Process Res. Dev. 2012, 16, 1953-1966. International Publication No. W02022 / 217008 describes crystalline forms of Zavegepant. IPCOM000271435D, IPCOM000273266D, International Publication No. WO2024 / 100599, and International Publication No. W02025 / 003905 describe crystalline forms of Zavegepant HC1. The entire contents of each of the foregoing publications are incorporated by reference herein.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0006] Polymorphism, the occurrence of different crystalline forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differential scanning calorimetry (“DSC”)), X-ray diffraction (“XRD”) pattern, infrared absorption fingerprint, and solid state (13C) NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound.
[0007] Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
[0008] Discovering new salt, solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemical / physical stability). For at least these reasons, there is a need for additional salts and solid state forms (including solvated forms) of Zavegepant.Attorney Docket: APIllO-WOOl (2222-224 PCT)SUMMARY OF THE DISCLOSURE
[0009] The present disclosure provides crystalline polymorphs of Zavegepant hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof. These crystalline polymorphs can be used to prepare other solid state forms of Zavegepant hydrochloride, other Zavegepant salts and their solid state forms. Particularly, the present disclosure provides crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride.
[0010] The present disclosure also provides uses of the said solid state forms of Zavegepant hydrochloride in the preparation of other solid state forms of Zavegepant hydrochloride or other salts and their solid state forms thereof.
[0011] The present disclosure provides crystalline polymorphs of Zavegepant hydrochloride for use in medicine, including for the acute treatment of migraine, for the prevention of migraine, or headaches.
[0012] The present disclosure also encompasses the use of crystalline polymorphs of Zavegepant hydrochloride of the present disclosure for the preparation of pharmaceutical compositions and / or formulations, particularly pharmaceutical compositions or formulations for oral or intranasal administration, and especially for intranasal administration. More particularly, the present disclosure encompasses the use of crystalline polymorphs of Zavegepant hydrochloride of the present disclosure for the preparation of pharmaceutical compositions or formulations particularly comprising solid Zavegepant hydrochloride, especially wherein the pharmaceutical compositions or formulations comprise solid Zavegepant hydrochloride. The pharmaceutical composition or formulation may be a solid dosage form (particularly for oral administration), especially tablets, powders, capsules, suppositories, sachets, troches, and lozenges; or may be in the form of a liquid (particularly for intravenous or intranasal, more particularly intranasal administration), especially a liquid, suspension, and elixir. Most preferably, the pharmaceutical composition or pharmaceutical formulation is a solution or suspension, particularly a solution or suspension for intranasal administration.
[0013] In another aspect, the present disclosure provides pharmaceutical compositions comprising crystalline polymorphs of Zavegepant hydrochloride according to the present disclosure. The pharmaceutical composition may particularly comprise solid Zavegepant hydrochloride, and may be a solid dosage form (particularly for oral administration), especially tablets, powders, capsules, suppositories, sachets, troches, and lozenges; or may be in the form ofAttorney Docket: APIllO-WOOl (2222-224 PCT)a liquid comprising solid Zavegepant hydrochloride (particularly for intravenous or intranasal, more particularly intranasal administration), especially liquid, suspension, and elixir. Most preferably, the pharmaceutical composition or pharmaceutical formulation is a suspension, particularly a suspension for intranasal administration. Pharmaceutical compositions according to any aspect of the present disclosure may include intranasal or oral dosage forms. Particularly, the pharmaceutical compositions may be an intranasal dosage form. More particularly, the pharmaceutical composition may be in the form of a liquid or a suspension, preferably a suspension, preferably for intranasal administration.
[0014] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Zavegepant hydrochloride with at least one pharmaceutically acceptable excipient. Particularly, the pharmaceutical compositions may comprise pharmaceutically acceptable excipient suitable for preparing an oral or intranasal dosage form, especially an intranasal dosage form. More particularly, the pharmaceutical compositions or formulations comprise solid Zavegepant hydrochloride. The pharmaceutical composition or formulation may be a solid dosage form (particularly for oral administration), especially tablets, powders, capsules, suppositories, sachets, troches, and lozenges; or may be in the form of a liquid (particularly for intravenous or intranasal, more particularly intranasal administration), especially a liquid, suspension, and elixir. Most preferably, the pharmaceutical composition or pharmaceutical formulation is a suspension, particularly a suspension for intranasal administration. More particularly, the pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients which are suitable for preparing a liquid or a suspension, preferably a suspension, for intranasal administration.
[0015] The crystalline polymorph of Zavegepant hydrochloride as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorph of Zavegepant hydrochloride may be used as medicaments, such as for the acute treatment of migraine, for the prevention of migraine, or headaches.
[0016] The present disclosure also provides methods of treating migraine, preventing migraine or treating headaches, by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Zavegepant hydrochloride of the presentAttorney Docket: APHlO-WOOl (2222-224 PCT)disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from migraine or headaches, or otherwise in need of the treatment.
[0017] The present disclosure also provides uses of crystalline polymorphs of Zavegepant hydrochloride of the present disclosure, or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating e.g., migraine or headaches, or for preventing migraine. The medicament may be administered as an intranasal dosage form, or may be administered as an oral dosage form, particularly an intranasal dosage form. More particularly, the medicament may be in the form of a liquid or a suspension, preferably a suspension, for intranasal administration.
[0018] According to any aspect or embodiment of the present disclosure, pharmaceutical compositions or formulations for the treatment of migraine or headaches are preferably in the form of an intranasal dosage form (for example in the form of a liquid or a suspension for intranasal administration). According to any aspect or embodiment of the present disclosure, pharmaceutical compositions or formulations for the prevention of migraine are preferably in the form of an oral dosage form.BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 shows an X-ray powder diffraction (“XRPD”) pattern of crystalline Zavegepant hydrochloride, prepared according to Example 1.
[0020] Figure 2 shows an XRPD pattern of crystalline Zavegepant hydrochloride form C6.
[0021] Figure 3 shows Thermogravimetric analysis (“TGA”) thermogram of crystalline Zavegepant hydrochloride form C6.
[0022] Figure 4 shows an XRPD pattern of crystalline Zavegepant hydrochloride, prepared according to Example 3.DETAILED DESCRIPTION OF THE DISCLOSURE
[0023] The present disclosure encompasses solid state forms of Zavegepant hydrochloride, including crystalline polymorphs of Zavegepant hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof. Particularly, the present disclosure provides crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride.
[0024] Solid state properties of Zavegepant hydrochloride and crystalline polymorphs thereof can be influenced by controlling the conditions under which Zavegepant and crystalline polymorphs thereof are obtained in solid form.Attorney Docket: API110-W001 (2222-224 PCT)
[0025] A solid state form (or polymorph) may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms. As used herein in this context, the expression “substantially free of any other forms” will be understood to mean that the solid state form contains about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD. Thus, a crystalline polymorph of Zavegepant hydrochloride described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w / w), greater than about 90% (w / w), greater than about 95% (w / w), greater than about 98% (w / w), greater than about 99% (w / w), or about 100% of the subject crystalline polymorph of Zavegepant hydrochloride. In some embodiments of the disclosure, the described crystalline polymorph of Zavegepant hydrochloride may contain from about 1% to about 20% (w / w), from about 5% to about 20% (w / w), or from about 5% to about 10% (w / w) of one or more other crystalline polymorph of the same Zavegepant hydrochloride.
[0026] Depending on which other crystalline polymorphs a comparison is made, the crystalline polymorphs of Zavegepant hydrochloride of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and / or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density. In particular, compared to known forms, the Zavegepant hydrochloride of the present disclosure (preferably crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, and more particularly crystalline Zavegepant hydrochloride methyl ethyl ketone solvate Form C6) may have the following advantageous properties: good solubility, good bulk properties such as flowability and / or bulk density. The crystalline Zavegepant hydrochloride Form C6 of the present disclosure is particularly useful as an intermediate for the preparation of other solid state forms of Zavegepant, Zavegepant hydrochloride or other Zavegepant salts, preferably Zavegepant hydrochloride.
[0027] A compound may be referred to herein as chemically pure or purified compound or as substantially free of any other compounds. As used herein in this context, the expression “substantially free of any other compounds” will be understood to mean that the pure compound contains about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2%Attorney Docket: APIllO-WOOl (2222-224 PCT)(w / w) or less, about 1% (w / w) or less, or about 0% of any other compound as measured, for example, by HPLC. Thus, pure or purified Zavegepant or Zavegepant hydrochloride described herein as substantially free of any compounds would be understood to contain greater than about 80% (w / w), greater than about 90% (w / w), greater than about 95% (w / w), greater than about 98% (w / w), greater than about 99% (w / w), or about 100% of the subject Zavegepant or Zavegepant hydrochloride. In some embodiments of the disclosure, the described pure or purified Zavegepant or Zavegepant hydrochloride may contain from about 1% to about 20% (w / w), from about 5% to about 20% (w / w), or from about 5% to about 10% (w / w) of one or more other compounds.
[0028] In specific embodiments, the above described pure or purified Zavegepant or Zavegepant hydrochloride may relate to enantiomeric purity, i.e., pure or purified Zavegepant or Zavegepant hydrochloride refers to Zavegepant or Zavegepant hydrochloride that is substantially free of enantiomers of Zavegepant or Zavegepant hydrochloride.
[0029] A solid state form, such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone. In any event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms. A crystal form of Zavegepant referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Zavegepant characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
[0030] As used herein, and unless stated otherwise, the term “anhydrous” in relation to crystalline forms of Zavegepant hydrochloride, relates to a crystalline form of ZavegepantAttorney Docket: API110-W001 (2222-224 PCT)hydrochloride, which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, unless otherwise indicated, an “anhydrous” form would generally not contain more than 1% (w / w), of either water or organic solvents as measured for example by TGA.
[0031] The term “solvate,” as used herein and unless indicated otherwise, refers to a crystal form that incorporates a solvent in the crystal structure. When the solvent is water, the solvate is often referred to as a “hydrate.” The solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
[0032] As used herein, the term “isolated” in reference to crystalline polymorph of Zavegepant hydrochloride of the present disclosure corresponds to a crystalline polymorph of Zavegepant hydrochloride that is physically separated from the reaction mixture in which it is formed.
[0033] As used herein, unless stated otherwise, the XRPD measurements are taken using copper Ka radiation wavelength 1.54187 A. XRPD peaks reported herein are measured using CuK a radiation, X = 1.54187 A, preferably at a temperature of 25 ± 3°C.
[0034] As used herein, unless stated otherwise, unit cell data were obtained at 293 ± 3 K.
[0035] A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to “room temperature” or “ambient temperature,” often abbreviated as “RT.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is from about 20 °C to about 30 °C, or about 22 °C to about 27 °C, or about 25 °C.
[0036] The amount of solvent employed in a chemical process, e.g., a reaction or crystallization, may be referred to herein as a number of “volumes” or “vol” or “V.” For example, a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent. In this context, this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent. In another context, the term “v / v” may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v / v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.Attorney Docket: API110-W001 (2222-224 PCT)
[0037] A process or step may be referred to herein as being carried out “overnight.” This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.
[0038] As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, reduced pressure is about 10 mbar to about 50 mbar.
[0039] As used herein and unless indicated otherwise, the term “ambient conditions” refer to atmospheric pressure and a temperature of 22-24 °C.
[0040] According to any aspect or embodiment of the present disclosure, the Zavegepant or Zavegepant hydrochloride, particularly Zavegepant hydrochloride methyl ethyl ketone solvate, and preferably Zavegepant hydrochloride Form C6, may be enantiomerically pure. By enantiomerically pure, it is meant that the Zavegepant or Zavegepant hydrochloride (preferably Zavegepant hydrochloride methyl ethyl ketone solvate, particularly Zavegepant hydrochloride Form C6) is substantially free of enantiomers of Zavegepant or Zavegepant hydrochloride. In particular, in any aspect or embodiment of the present disclosure, the Zavegepant or Zavegepant hydrochloride (particularly Zavegepant hydrochloride methyl ethyl ketone solvate and preferably Zavegepant hydrochloride Form C6) may be enantiomerically pure, and in particular contains: 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of other enantiomers of Zavegepant or Zavegepant hydrochloride respectively, as measured, for example, by HPLC.
[0041] Crystalline forms of Zavegepant hydrochloride (particularly Zavegepant hydrochloride methyl ethyl ketone solvate, and preferably Zavegepant hydrochloride Form C6), according to any aspect or embodiment may be substantially free of any other crystalline forms of Zavegepant hydrochloride. In particular, the crystalline forms Zavegepant hydrochloride (particularly Zavegepant hydrochloride methyl ethyl ketone solvate, and preferably Zavegepant hydrochloride Form C6), may contain: about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of any other crystalline forms of Zavegepant hydrochloride, as measured, for example, by XRPD. Thus, crystalline forms of Zavegepant hydrochloride (particularly Zavegepant hydrochloride methyl ethyl ketone solvate, and preferably Zavegepant hydrochloride Form C6) described herein as substantially free of any other crystalline forms would be understood to contain greater than about 80% (w / w), greater thanAttorney Docket: API110-W001 (2222-224 PCT)about 90% (w / w), greater than about 95% (w / w), greater than about 98% (w / w), greater than about 99% (w / w), or about 100% of Form C6 of Zavegepant hydrochloride. According to any aspect or embodiment of the present disclosure, crystalline forms of Zavegepant hydrochloride (particularly Zavegepant hydrochloride methyl ethyl ketone solvate, and preferably Zavegepant hydrochloride Form C6) may be substantially free of amorphous Zavegepant hydrochloride. In particular, the crystalline forms of Zavegepant hydrochloride may contain: about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of amorphous Zavegepant hydrochloride, as measured, for example, by XRPD.
[0042] The present disclosure includes a methyl ethyl ketone solvate of Zavegepant hydrochloride. Specifically, the present disclosure includes a crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride, designated Form C6. Crystalline Form C6 may be described by an XRPD pattern having characteristic peaks at 9.3 , 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta.
[0043] Crystalline Form C6 may be further characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any one, two, three, four, or five additional peaks at 13.6; 18.8; 20.2; 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.
[0044] Crystalline Form C6 may be described by an XRPD pattern having characteristic peaks at 9.3; 12.0; 13.6; 16.9; 18.1; 18.8; 19.4; 20.2; 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.
[0045] Typically, crystalline Form C6 XRPD pattern include the following peaks: 7.2, 9.3, 10.1, 10.4, 10.6, 12.0, 12.2, 12.6, 12.9, 13.1, 13.6, 14.3, 14.4, 14.9, 15.3, 15.7, 16.3, 16.4, 16.9, 17.0, 17.3, 18.1, 18.3, 18.7, 18.8, 19.3, 19.8, 20.2, 20.3, 20.4, 20.5, 20.6, 20.8, 20.9, 21.2, 21.4, 21.6, 21.7, 21.8, 22.7, 22.8, 23.0, 23.4, 24.1, 24.2, 24.6, 24.7, 24.8, 24.9, 25.5, 25.6, 25.9, 26.0, 26.4, and 26.6 degrees 2-theta ± 0.2 degrees 2-theta. Crystalline Form C6 can be characterized by characteristic group of peaks selected from this list, for example having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta.
[0046] Alternatively, crystalline Form C6 may be described by an XRPD pattern substantially as depicted in Figure 2.
[0047] Crystalline Form C6 may be also described by the following unit cell data, which is preferably obtained at 293K ± 3 K (preferably using Le Bail fitting method):Attorney Docket: APIllO-WOOl (2222-224 PCT)Unit cell parametercell length a 11.243 Acell length b 13.974 Acell length c 26.054 Acell angle alpha 90°cell angle beta 90°cell angle gamma 90°
[0048] Particularly, crystalline Form C6 may be also described by the following unit cell data:Form C6 (MEKUnit cell parameter solvate), Ue-Bail 293Kcell length a 11.243 Acell length b 13.974 Acell length c 26.054 Acell angle alpha 90°cell angle beta 90°cell angle gamma 90°cell volume 4093.0 A3symmetry cell setting orthorhombicSymmetry space group name P 21 21 21
[0049] A typical TGA thermogram of crystalline Form C6 is shown in Figure 3. Typically, the solvent content is of about 7.7-11.5% (w / w), preferably 8.4-9.6% (w / w).
[0050] According to any aspect or embodiment of the present disclosure, the crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, preferably crystalline Form C6 of Zavegepant hydrochloride, is preferably isolated.
[0051] Crystalline Form C6 of Zavegepant hydrochloride may be either polymorphically pure, or in a mixture of additional crystalline forms of Zavegepant hydrochloride.
[0052] Crystalline Form C6 of Zavegepant may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in any one or more of Figure 1, Figure 2, or Figure 4, and combinations thereof.
[0053] The crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, preferably crystalline Form C6 of Zavegepant hydrochloride may have one or more advantageous properties, as discussed herein above.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0054] Particularly, crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, can be obtained directly from the synthesis reaction in a simple and safe manner. The crystallization solvent, methyl ethyl ketone, has a higher boiling point compared to acetone, which boils at 56 °C, at atmospheric pressure. In addition, under regular conditions, such as temperature of about 25 °C, acetone exhibits a vapor pressure of 30.8 kPa, compared with 12.6 kPa for methyl ethyl ketone. These properties indicate lower volatility of methyl ethyl ketone compared to acetone, and results in reduced VOC emissions under typical process conditions. Consequently, methyl ethyl ketone is suitable and favorable as a process solvent from an environmental and occupational exposure standpoint. It is also suitable as a co-solvent with common alcoholic solvent during recrystallization.
[0055] Crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, particularly crystalline form C6, or a crystalline solid comprising form C6 can be prepared by a process comprising precipitating Zavegepant hydrochloride from a mixture comprising ethanol and methyl ethyl ketone (“MEK”). The process may include dissolving Zavegepant hydrochloride in ethanol and adding MEK to obtain a suspension, from which crystalline form C6 precipitates. Dissolution of Zavegepant hydrochloride in ethanol may be achieved by first suspending Zavegepant hydrochloride in ethanol and then heating, to a temperature in which a solution is formed. Ethanol may be used in an amount of: about 15 ml to about 35 ml, about 20 ml to about 30 ml, about 20 ml to about 25 ml, or about 22 to about 23 ml, per gram of Zavegepant hydrochloride. The solution may then be cooled and optionally filtered. The solution may then be heated, for example to a temperature of about 55 °C to about 60 °C. MEK is typically added to the solution in a drop- wise manner, for example over a period of from about 10 minutes to 30 minutes. MEK may be used in an amount of about 15 ml to about 35 ml, about 20 ml to about 30 ml, about 20 ml to about 28 ml, or about 22 to about 23 ml, per gram of Zavegepant hydrochloride. The volume ratio of MEK to ethanol may be: about 2:1 to about 1:2, about 1.5:1 to about 1:1.5, about 1.2:1 to about 1:1.1, or about 1:1. Typically, after the addition of MEK, a suspension is formed, which can be further maintained at a temperature of about 55 °C to about 60 °C. The suspension can then be cooled down, for example to about room temperature. The solid is then filtered and optionally washed with methyl ethyl ketone.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0056] The above crystalline polymorphs can be used to prepare other crystalline polymorphs of Zavegepant hydrochloride, other Zavegepant salts and their solid state forms. Solid state forms may be crystalline polymorphs, co-crystals and complexes of Zavegepant or of Zavegepant salt.
[0057] In particular crystalline Zavegepant hydrochloride methyl ethyl ketone solvate may be advantageously used to prepare other crystalline forms of Zavegepant, Zavegepant hydrochloride, and other Zavegepant salts, preferably Zavegepant hydrochloride. According to any aspect or embodiment, the disclosed processes may further comprise converting the Zavegepant hydrochloride methyl ethyl ketone solvate, preferably Form C6, to another solid state form of Zavegepant, Zavegepant hydrochloride, or another salt of Zavegepant. According to any aspect or embodiment, the disclosed processes may further comprise combining the Zavegepant hydrochloride methyl ethyl ketone solvate, preferably form C6 of Zavegepant hydrochloride, or another solid state form of Zavegepant, Zavegepant hydrochloride or another salt of Zavegepant, with at least one pharmaceutically acceptable excipient to prepare a pharmaceutical composition or a pharmaceutical formulation, preferably an intranasal formulation.
[0058] The present disclosure encompasses a process for preparing other solid state forms of Zavegepant hydrochloride and their solid state forms thereof. The process includes preparing any one of the crystalline polymorphs of Zavegepant hydrochloride, preferably crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, and more preferably crystalline Form C6 of Zavegepant hydrochloride, by the processes of the present disclosure. The process may further comprise converting said crystalline polymorph of Zavegepant hydrochloride to other crystalline polymorph of Zavegepant or to other Zavegepant salt.
[0059] The present disclosure provides the above described crystalline polymorphs of Zavegepant hydrochloride (preferably crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, and more preferably crystalline Form 6 of Zavegepant hydrochloride) for use in the preparation of pharmaceutical compositions comprising Zavegepant hydrochloride and / or crystalline polymorphs thereof.
[0060] The present disclosure also encompasses the use of crystalline polymorphs of Zavegepant hydrochloride (preferably crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, and more preferably crystalline Form 6 of Zavegepant hydrochloride) of the present disclosure for the preparation of pharmaceutical compositions of crystalline polymorph Zavegepant hydrochloride and / or crystalline polymorphs thereof. Particularly, the pharmaceuticalAttorney Docket: APIllO-WOOl (2222-224 PCT)compositions may be used for intranasal or oral administration, and more particularly for intranasal administration.
[0061] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Zavegepant hydrochloride of the present disclosure (preferably crystalline Zavegepant hydrochloride methyl ethyl ketone solvate, and more preferably crystalline Form 6 of Zavegepant hydrochloride) with at least one pharmaceutically acceptable excipient. Particularly, the pharmaceutical compositions may comprise pharmaceutically acceptable excipient suitable for making formulation of intranasal or oral administration, and more particularly for intranasal administration. Pharmaceutical combinations or formulations of the present disclosure contain any one or a combination of the solid state forms of Zavegepant hydrochloride of the present disclosure. In addition to the active ingredient, the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes. For example, excipients may be added to assist in formation of formulation suitable for intranasal administration.
[0062] Diluents increase the bulk of a solid pharmaceutical composition, and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle. Diluents for solid compositions include, for example, microcry stalline cellulose (e.g., Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
[0063] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g., carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g., Klucel®), hydroxypropyl methyl cellulose (e.g., Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g., Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0064] The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach can be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
[0065] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
[0066] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and die. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
[0067] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
[0068] Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and / or facilitate patient identification of the product and unit dosage level.
[0069] In liquid pharmaceutical compositions of the present disclosure, Zavegepant and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
[0070] Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble inAttorney Docket: APIllO-WOOl (2222-224 PCT)the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present disclosure include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
[0071] Liquid pharmaceutical compositions of the present disclosure can also contain a viscosity enhancing agent to improve the mouth-feel of the product and / or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.
[0072] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.
[0073] Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.
[0074] According to the present disclosure, a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[0075] The solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, intranasal and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
[0076] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0077] The dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell. The shell can be made from gelatin and optionally contain a plasticizer such as glycerin and / or sorbitol, an opacifying agent and / or colorant.
[0078] The active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.
[0079] A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and / or milled, dried, and then screened and / or milled to the desired particle size. The granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and / or a lubricant.
[0080] A tableting composition can be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.
[0081] As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
[0082] A capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.
[0083] A pharmaceutical formulation of Zaveg epant hydrochloride can be administered. For example, it can be administered intranasally or orally. Zavegepant hydrochloride may be formulated for administration to a mammal, in embodiments to a human, by injection. Zavegepant hydrochloride can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection. The formulation can contain one or more solvents. A suitable solventAttorney Docket: APHlO-WOOl (2222-224 PCT)can be selected by considering the solvent's physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity. Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and antioxidants, among others. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.
[0084] The crystalline polymorphs of Zavegepant hydrochloride and the pharmaceutical compositions and / or formulations of Zavegepant hydrochloride of the present disclosure can be used as medicaments, in embodiments in the treatment of migraine or headaches. The medicament may preferably be administered in intranasal or oral form, and more preferably in intranasal form.
[0085] The present disclosure also provides methods of treating migraine or headaches by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Zavegepant hydrochloride of the present disclosure, or at least one of the above pharmaceutical compositions and / or formulations, to a subject in need of the treatment.
[0086] Having thus described the disclosure with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the disclosure as described and illustrated that do not depart from the spirit and scope of the disclosure as disclosed in the specification. The Examples are set forth to aid in understanding the disclosure but are not intended to, and should not be construed to limit its scope in any way.Powder X-ray Diffraction (“XRPD”) method:
[0087] Powder X-ray Diffraction was performed on an X-Ray powder diffractometer PanAlytical EMPYREAN; CuKa radiation (A. = 1.54187 A); pixCel detector with active length 2.140 degrees 2-theta; laboratory temperature 25 ± 3 °C; zero background sample holders. Prior to analysis, the samples were gently ground using a mortar and pestle to obtain a fine powder. The ground sample was adjusted into a cavity of the sample holder and the surface of the sample was smoothed using a cover glass. Measurements were obtained at a temperature of 25 ± 3 °C.Measurement parametersScan range: 3 -40 degrees 2-thetaScan mode: continuousStep size: 0.0131 degreesAttorney Docket: API110-W001 (2222-224 PCT)Step size: 41 sSample spin: 60 rpmSample holder: zero background silicon platePowder X-ray Diffraction (“XRPD”) - capillary method:
[0088] In order to avoid any desolvatation of solvates, the solid sample together with mother liquor was injected to the borosilicate-glass capillary of d=1.0 mm. Then the solid part was concentrated in the tip of the capillary in benchtop centrifuge. Powder diffraction data were collected using the Debye-Scherrer transmission configuration on the powder diffractometer Empyrean of PANalytical (XCu,Ka = 1.541874 A) that was equipped with a focusing mirror, capillary holder, and PIXcel3Ddetector. The pattern was measured from 3-80° 2-Theta with 0.013° step size and with overall 20 h measurement time. Halo effect facilitated by amorphous solvent was subtracted.Unit cell parameters - method:
[0089] Unit cell data were obtained at 293 ± 3 K. Peak positions were determined in DASH software. Indexing was done in DICVOL14 software. Identity and purity of sample was provided by Le-Bail fit.Thermogravimetric analysis (“TGA”) method:
[0090] TGA analysis was conducted using the following conditions:Equipment: TA Discovery;Crucibles: Aluminum, 100 pl;Heating range: 20 - 200 °C;Heating rate: 10°C / min;Purging gas: Nitrogen;Purging gas flow: 25 ml / min.Attorney Docket: APIllO-WOOl (2222-224 PCT)EXAMPLESPreparation of starting materials
[0091] Zavegepant can be prepared according to methods known from the literature, for example U.S. Patent No. 8,481,546 or according to International Publication No. WO2022 / 217008. The entire contents of the foregoing patent and publication are incorporated by reference herein.
[0092] Zavegepant hydrochloride may be prepared by converting Zavegepant prepared to general methods, such as those mentioned above, to a hydrochloride salt.Preparation of amorphous Zavegepant hydrochloride:
[0093] Zavegepant hydrochloride (100 mg) was dissolved in ethanol (1 ml) at elevated temperature. The obtained clear solution was cooled down to a temperature of about 20 °C and heptane was added dropwise (300 pl). The product started to precipitate after a few minutes of stirring. The obtained suspension was stirred for 60 minutes. Then, the solid was filtered and dried under vacuum for about 15 minutes. The solid was analyzed by XRPD; amorphous was obtained.Example 1: Preparation of Zavegepant hydrochloride - crystalline solid comprising form C6
[0094] Zavegepant hydrochloride (1.0 g) was suspended in ethanol (22 mL) and the suspension was heated to boiling until the solid dissolved. The obtained solution was left to cool to a temperature of about 45 °C during a period of about 10 min. The solution was filtered through a syringe filter and the flask was washed with ethanol (1 mL). The solution was heated to a temperature of from about 55 °C to about 60 °C. Methyl ethyl ketone (23 mL) was added dropwise during a period of about 20 min. The obtained suspension was stirred for about 21 hours at a temperature of from about 55 °C to about 60 °C. Then suspension was left to cool to about 25 °C during a period of about 25 min and further stirred for about 2 hours. The suspension was filtered, and the filter cake was washed with methyl ethyl ketone (3 x 5 mL). The solid was analyzed by XRPD; a crystalline solid comprising form C6 was obtained. An XRPD pattern is shown in Ligure 1.Example 2: Preparation of crystalline Zavegepant hydrochloride form C6
[0095] Zavegepant hydrochloride (200 mg) was dissolved in ethanol (23 vol.; 4.6 mL) by heating to about 75 °C. The obtained solution was cooled to about 50 °C during a period of aboutAttorney Docket: API110-W001 (2222-224 PCT)20 minutes and methyl ethyl ketone (23 vol.; 4.6 mL) was added dropwise followed by stirring at about 50 °C for about 90 minutes. The obtained suspension was diluted with ethanol (5 vol.; 1 mL) and cooled to about room temperature over a period of about 1 hour. The suspension was stirred overnight and used for capillary XRD measurement, the solid was analyzed - Form C6 obtained. An XRPD pattern is shown in Figure 2.Example 3: Preparation of Zavegepant hydrochloride - crystalline solid comprising form C6
[0096] Zavegepant hydrochloride (1.0g) was suspended in ethanol (22 mL) and the suspension was heated to boiling until the solid dissolved. The resulting solution was left to cool to a temperature of about 45 °C during a period of about 10 min. The solution was filtered through a syringe filter, and the flask was washed with ethanol (1 mL). The solution was heated to a temperature of from about 55°C to about 60 °C. Methyl ethyl ketone (23 mL) was added dropwise during a period of about 20 min. The obtained suspension was stirred for about 21 hours at a temperature of from about 55 °C to about 60 °C. Then suspension was left to cool to about 25 °C over a period of about 25 min and further stirred for about 2 hours. The suspension was filtered, and the filter cake was washed with methyl ethyl ketone (3 x 5 mL) and dried at about 65 °C for about 23 hrs and was analyzed by XRPD; a crystalline solid comprising form C6 was obtained. An XRPD pattern is shown in Figure 4.Attorney Docket: APIllO-WOOl (2222-224 PCT)
[0097] Further aspects and embodiments of the disclosure are set out in the following numbered clauses:1. Methyl ethyl ketone solvate of Zavegepant hydrochloride.2. Methyl ethyl ketone solvate of Zavegepant hydrochloride according to Clause 1, which may be designated form C6, which is characterized by data selected from:(a) an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta;(b) an XRPD pattern substantially as depicted in Figure 1 or in Figure 2; (c) unit cell data according to the table (preferably (obtained at 293K ±3 K, preferably using Le Bail fitting method):Unit cell parametercell length a 11.243 Acell length b 13.974 Acell length c 26.054 Acell angle alpha 90°cell angle beta 90°cell angle gamma 90°or unit cell data according to the table:Form C6 (MEK solvate),Unit cell parameterEe-Bail 293 Kcell length a 11.243 Acell length b 13.974 Acell length c 26.054 Acell angle alpha 90°cell angle beta 90°cell angle gamma 90°cell volume 4093.0 A3symmetry cell setting orthorhombicsymmetry space group name P 21 21 21and(d) any combination of these data.Attorney Docket: APIllO-WOOl (2222-224 PCT)Methyl ethyl ketone solvate of Zavegepant hydrochloride according to Clause 2, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to Clause 2 or Clause 3, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any one, two, three, four or five additional peaks at 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1, 2, 3, and 4, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any one additional peaks at 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1 , 2, 3, and 4, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any two additional peaks at 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; wherein the two additional peaks are selected from: 13.6 and 18.8 degrees 2-theta ± 0.2 degrees 2-theta; 13.6 and 20.2 degrees 2-theta ± 0.2 degrees 2-theta; 13.6 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; and 13.6 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 18.8 and 20.2 degrees 2-theta± 0.2 degrees 2-theta; 18.8 and24.1 degrees 2-theta± 0.2 degrees 2-theta, 18.8 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 20.2 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta, 20.2 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta, or 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1 , 2, 3, and 4, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any three additional peaks at 13.6, 18.8, 20.2, 24.1 and24.8 degrees 2-theta± 0.2 degrees 2-theta; wherein the three additional peaks are selected from: 13.6, 18.8 and 20.2 degrees 2-theta ± 0.2 degrees 2-Attorney Docket: APIllO-WOOl (2222-224 PCT)theta; 13.6, 18.8 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 18.8 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; and 13.6, 20.2 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 20.2, and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 18.8, 20.2 and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; 18.8, 20.2 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 18.8, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1, 2, 3, and 4, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any four additional peaks at 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; wherein the four additional peaks are selected from: 13.6, 18.8, 20.2, and 24.1 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 18.8, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; 13.6, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta; and 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1 , 2, 3, and 4, which is characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 13.6, 16.9, 18.1, 18.8, 19.4, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1, 2, 3, and 4, which is characterized by an XRPD pattern having characteristic peaks at 7.2, 9.3, 10.1, 10.4, 10.6, 12.0, 12.2, 12.6, 12.9, 13.1, 13.6, 14.3, 14.4, 14.9, 15.3, 15.7, 16.3, 16.4, 16.9, 17.0, 17.3, 18.1, 18.3, 18.7, 18.8, 19.3, 19.8, 20.2, 20.3, 20.4, 20.5, 20.6, 20.8, 20.9, 21.2, 21.4, 21.6, 21.7, 21.8, 22.7, 22.8, 23.0, 23.4, 24.1, 24.2, 24.6, 24.7, 24.8, 24.9, 25.5, 25.6, 25.9, 26.0, 26.4, and 26.6 degrees 2-theta ± 0.2 degrees 2-theta.Attorney Docket: APIllO-WOOl (2222-224 PCT)Methyl ethyl ketone solvate of Zavegepant hydrochloride form C6 according to any of Clauses 1-10, which is characterized by having a methyl ethyl ketone content (w / w) of about: 7.7 to about 11.5%, about 8.0% to about 10.2%, or about 8.4% to about 9.6%; or which is characterized by TGA thermogram as shown in Figure 3.Methyl ethyl ketone solvate of Zavegepant hydrochloride form C6 according to any of Clauses 1-11, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Zavegepant hydrochloride.Methyl ethyl ketone solvate of Zavegepant hydrochloride form C6 according to any of Clauses 1-12, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Zavegepant hydrochloride.Methyl ethyl ketone solvate of Zavegepant hydrochloride according to any preceding clause, which is chemically pure.A pharmaceutical composition comprising a crystalline form according to any preceding clause.A pharmaceutical formulation comprising a crystalline form according to any of Clauses 1 to 14, or a pharmaceutical composition of Clause 15, and at least one pharmaceutically acceptable excipient.A pharmaceutical formulation according to Clause 16, optionally in the form of a liquid or suspension, and / or wherein the formulation is an intranasal formulation.A process for preparing a pharmaceutical formulation according to any of Clauses 16 and 17, comprising combining a crystalline form according to any of Clauses 1 to 14, or aAttorney Docket: APIllO-WOOl (2222-224 PCT)pharmaceutical composition of Clause 15, with at least one pharmaceutically acceptable excipient.Use of a crystalline form according to any of Clauses 1 to 14, for the preparation of a pharmaceutical composition and / or formulation, and optionally wherein the pharmaceutical formulation is an intranasal formulation.A crystalline form according to any of Clauses 1 to 14; a pharmaceutical composition according to Clause 15; or a pharmaceutical formulation according to any of Clauses 16 and 17, for use as a medicament.A crystalline form according to any of Clauses 1 to 14; a pharmaceutical composition according to Clause 15; or a pharmaceutical formulation according to any of Clauses 16 and 17, for use in the treatment or prevention of migraine; or headaches.A method of treating or preventing migraine; or headaches, comprising administering a therapeutically effective amount of a crystalline form according to any of Clauses 1 to 14; a pharmaceutical composition according to Clause 15; or a pharmaceutical formulation according to any of Clauses 16 and 17, to a subject in need of the treatment.The method according to Clause 22, wherein the treatment is administered intranasally.A crystalline form according to any of Clauses 1 to 14; a pharmaceutical composition according to Clause 15; or a pharmaceutical formulation according to any of Clauses 16 and 17, for the manufacture of a medicament for the treatment of migraine or headaches.Use of a crystalline form according to any of Clauses 1 to 14, in the preparation of another solid state form of Zavegepant, Zavegepant salt, co-crystal or complex of Zavegepant or Zavegepant salt.Attorney Docket: API110-W001 (2222-224 PCT)A process for preparing solid state form of Zavegepant, Zavegepant salt and their crystalline polymorph, co-crystals or complex thereof, comprising preparing a crystalline form according to any of Clauses 1 to 14, and converting it to another solid state form of Zavegepant, Zavegepant salt or a crystalline polymorph, co-crystal or complex thereof.A process for preparing methyl ethyl ketone solvate of Zavegepant hydrochloride according to any of Clauses 1 to 14, comprising precipitating Zavegepant hydrochloride from a mixture comprising ethanol and methyl ethyl ketone (“MEK”).A process according to Clause 27, which comprises dissolving Zavegepant hydrochloride in ethanol and adding MEK to obtain a suspension.A process according to any of Clauses 27 and 28, wherein ethanol is used in an amount of: about 15 ml to about 35 ml, about 20 ml to about 30 ml, about 20 ml to about 25 ml, or about 22 to about 23 ml, per gram of Zavegepant hydrochloride.A process according to any of Clauses 27, 28 and 29, wherein MEK is used in an amount of about 15 ml to about 35 ml, about 20 ml to about 30 ml, about 20 ml to about 28 ml, or about 22 to about 23 ml, per gram of Zavegepant hydrochloride.A process according to any of Clauses 27, 28, 29, and 30, wherein the volume ratio of MEK to ethanol may be: about 2:1 to about 1:2, about 1.5:1 to about 1:1.5, about 1.2:1 to about 1:1.1, or about 1:1.A process according to any of Clauses 28, 29, 30, and 31, further comprising heating the suspension, preferably to a temperature of about 55 °C to about 60 °C.A process according to any of Clauses 28, 29, 30, 31, and 32, further comprising cooling the suspension.Attorney Docket: APIllO-WOOl (2222-224 PCT)A process according to any of Clauses 28, 29, 30, 31, 32, and 33, further comprising filtering the solid from the suspension.A process according to Clause 34, further comprising washing the solid, preferably with methyl ethyl ketone.A process according to any of Clauses 27, 28, 29, 30, 31, 32, 33, 34, and 35, further comprising converting the Form C6 of Zavegepant hydrochloride to another solid state form of Zavegepant, Zavegepant hydrochloride, or another salt of Zavegepant.A process according to any of Clauses 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36, further comprising combining the Zavegepant hydrochloride methyl ethyl ketone solvate, preferably Form C6, or another solid state form of Zavegepant, Zavegepant hydrochloride or another salt of Zavegepant, with at least one pharmaceutically acceptable excipient to prepare a pharmaceutical composition or a pharmaceutical formulation, preferably an intranasal formulation.
Claims
Attorney Docket: API110-W001 (2222-224 PCT)CLAIMS1. A crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride.
2. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to claim 1, which is characterized by data selected from one or more of the following:(a) an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta;(b) an XRPD pattern substantially as depicted in Figure 1 or in Figure 2; or(c) unit cell data according to the table:Unit cell parametercell length a 11.243 Acell length b 13.974 Acell length c 26.054 Acell angle alpha 90°cell angle beta 90°cell angle gamma 90°3. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 or 2, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta.
4. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1, 2, or 3, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 16.9, 18.1 and 19.4 degrees 2-theta ± 0.2 degrees 2-theta, and any one, two, three, four or five additional peaks at 13.6, 18.8, 20.2, 24.1 and 24.8 degrees 2-theta ± 0.2 degrees 2-theta.
5. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1, 2, 3, or 4, characterized by an XRPD pattern having characteristic peaks at 9.3, 12.0, 13.6, 16.9, 18.1, 18.8, 19.4, 20.2, 24.1 and 24.8 degrees 2-theta± 0.2 degrees 2-theta.
6. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claim 1, 2, 3, 4, or 5, characterized by an XRPD pattern having characteristic peaks at 7.2, 9.3, 10.1, 10.4, 10.6, 12.0, 12.2, 12.6, 12.9, 13.1, 13.6, 14.3, 14.4, 14.9, 15.3, 15.7, 16.3, 16.4, 16.9,Attorney Docket: API110-W001 (2222-224 PCT)17.0, 17.3, 18.1, 18.3, 18.7, 18.8, 19.3, 19.8, 20.2, 20.3, 20.4, 20.5, 20.6, 20.8, 20.9, 21.2, 21.4, 21.6, 21.7, 21.8, 22.7, 22.8, 23.0, 23.4, 24.1, 24.2, 24.6, 24.7, 24.8, 24.9, 25.5, 25.6, 25.9, 26.0, 26.4, and 26.6 degrees 2-theta ± 0.2 degrees 2-theta.
7. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1, 2, 3, 4, 5, or 6, which is characterized by having a methyl ethyl ketone content (w / w) of about: 7.7 to about 11.5%, about 8.0% to about 10.2%, or about 8.4% to about 9.6%; or which is characterized by TGA thermogram substantially as depicted in Figure 3.
8. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1, 2, 3, 4, 5, 6, or 7, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Zavegepant hydrochloride.
9. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1, 2, 3, 4, 5, 6, 7, or 8, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Zavegepant hydrochloride.
10. The crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any preceding claim, which is chemically pure.
11. A pharmaceutical composition comprising the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any preceding claim.
12. A pharmaceutical formulation comprising the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, or the pharmaceutical composition of claim 11 , and at least one pharmaceutically acceptable excipient.Attorney Docket: API110-W001 (2222-224 PCT)13. A pharmaceutical formulation according to claim 12, wherein the pharmaceutical formulation is in the form of a liquid or suspension, and / or wherein the pharmaceutical formulation is an intranasal formulation.
14. A process for preparing the pharmaceutical formulation according to any one of claims 12 or 13, comprising combining the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, or the pharmaceutical composition of claim 11, with at least one pharmaceutically acceptable excipient.
15. Use of the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, for the preparation of a pharmaceutical composition and / or formulation, and optionally wherein the pharmaceutical formulation is an intranasal formulation.
16. A crystalline form according to any one of claims 1 to 10, the pharmaceutical composition according to claim 11, or the pharmaceutical formulation according to any one of claims 12 or 13, for use as a medicament.
17. A crystalline form according to any one of claims 1 to 10, the pharmaceutical composition according to claim 11, or the pharmaceutical formulation according to any one of claims 12 or 13, for use in the treatment or prevention of migraine or headaches.
18. A method of treating or preventing migraine or headaches, the method comprising administering a therapeutically effective amount of the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, the pharmaceutical composition according to claim 11, or the pharmaceutical formulation according to any one of claims 12 or 13, to a subject in need of the treatment.
19. The method according to claim 18, wherein the treatment is administered intranasally.Attorney Docket: API110-W001 (2222-224 PCT)20. A crystalline form according to any one of claims 1 to 10, the pharmaceutical composition according to claim 11, or the pharmaceutical formulation according to any one of claims 12 or 13, for the manufacture of a medicament for the treatment of migraine or headaches.
21. Use of the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, in the preparation of another solid state form of Zavegepant, a Zavegepant salt, a co-crystal of Zavegepant or a Zavegepant salt, or a complex of Zavegepant or a Zavegepant salt.
22. A process for preparing a solid state form of Zavegepant, a Zavegepant salt, or a crystalline polymorph, co-crystal, or complex thereof, comprising preparing the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, and converting the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride to another solid state form of Zavegepant, a Zavegepant salt, or a crystalline polymorph, co-crystal, or complex thereof.
23. A process for preparing the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride according to any one of claims 1 to 10, comprising precipitating Zavegepant hydrochloride from a mixture comprising ethanol and methyl ethyl ketone (“MEK”).
24. The process according to claim 23, which comprises dissolving Zavegepant hydrochloride in ethanol and adding MEK to obtain a suspension.
25. The process according to claim 23 or claim 24, further comprising heating the suspension, preferably to a temperature of about 55 °C to about 60 °C.
26. The process according to any one of claims 24 or 25, further comprising cooling down the suspension.
27. The process according to claim 26, further comprising filtering the solid from the suspension.Attorney Docket: APIllO-WOOl (2222-224 PCT)28. The process according to claim 27, further comprising washing the solid, preferably with methyl ethyl ketone.
29. The process according to any one of claims 23, 24, 25, 26, 27, or 28, further comprising converting the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride to another solid state form of Zavegepant, Zavegepant hydrochloride, or another salt of Zavegepant.
30. The process according to any one of claims 22, 23, 24, 25, 26, 27, 28, or 29, further comprising combining the crystalline methyl ethyl ketone solvate of Zavegepant hydrochloride or another solid state form of Zavegepant, Zavegepant hydrochloride or another salt of Zavegepant, with at least one pharmaceutically acceptable excipient to prepare a pharmaceutical composition or a pharmaceutical formulation, preferably an intranasal formulation.
